 | • レポートコード：QYR9NV08707 • 出版社/出版日：QYResearch / 2019年11月14日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品・ヘルスケア |
| Single User | ￥525,000 (USD3,500) | ▷ お問い合わせ |
| Enterprise License | ￥1,050,000 (USD7,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| ※本調査レポートは、多発性硬化症（MS）治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、コパキソン（酢酸グラチラマー、共重合体1）、ノバントロン（ミトキサントロン）、ギレニア（フィンゴリモド、Fty720）、オーバジオ（テリフルノミド）、テクフィデラ（フマル酸ジメチル）、フィラテグラス（Sb683699、T-0047）、シポニモド（Baf312）、その他に、用途別には、RRMS、SPMS、PPMS、PRMSにセグメント区分し、多発性硬化症（MS）治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・多発性硬化症（MS）治療薬の世界市場概要 ・多発性硬化症（MS）治療薬の製造コスト構成分析 ・多発性硬化症（MS）治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・多発性硬化症（MS）治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・多発性硬化症（MS）治療薬のセグメント分析（種類別） （コパキソン（酢酸グラチラマー、共重合体1）、ノバントロン（ミトキサントロン）、ギレニア（フィンゴリモド、Fty720）、オーバジオ（テリフルノミド）、テクフィデラ（フマル酸ジメチル）、フィラテグラス（Sb683699、T-0047）、シポニモド（Baf312）、その他） ・多発性硬化症（MS）治療薬のセグメント分析（用途別） （RRMS、SPMS、PPMS、PRMS） ・多発性硬化症（MS）治療薬の主要メーカー別分析（生産拠点、製品概要、生産・売上実績） （Bayer AG、Bayhill Therapeutics、Biogen Idec、Cinnagen、Daiichi Sankyo、Eli Lilly、Fast Forward Llc、Antisense Therapeutics、Apitope、Five Prime Therapeutics、Genmab、Artielle Immunotherapeutics、Genzyme、Glaxosmithkline、Gw Pharmaceuticals、Innate Immunotherapeutics、） ・多発性硬化症（MS）治療薬の市場規模予測（2019年～2025年） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・マーケティングチャネル・流通業者・顧客 ・市場ダイナミクス（市場動向、機会、成長要因、課題、影響因子） ... |
The global Multiple Sclerosis (MS) Drugs market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
This report focuses on Multiple Sclerosis (MS) Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Multiple Sclerosis (MS) Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Multiple Sclerosis (MS) Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Multiple Sclerosis (MS) Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Bayer AG
Bayhill Therapeutics
Biogen Idec
Cinnagen
Daiichi Sankyo
Eli Lilly
Fast Forward Llc
Antisense Therapeutics
Apitope
Five Prime Therapeutics
Genmab
Artielle Immunotherapeutics
Genzyme
Glaxosmithkline
Gw Pharmaceuticals
Innate Immunotherapeutics
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
Copaxone (Glatiramer Acetate, Copolymer 1)
Novantrone (Mitoxantrone)
Gilenya (Fingolimod, Fty720)
Aubagio (Teriflunomide)
Tecfidera (Dimethyl Fumarate)
Firategrast (Sb683699, T-0047)
Siponimod (Baf312)
Others
Segment by Application
RRMS
SPMS
PPMS
PRMS
Table of Contents
Executive Summary
1 Industry Overview of Multiple Sclerosis (MS) Drugs
1.1 Definition of Multiple Sclerosis (MS) Drugs
1.2 Multiple Sclerosis (MS) Drugs Segment by Type
1.2.1 Global Multiple Sclerosis (MS) Drugs Production Growth Rate Comparison by Types (2014-2025)
1.2.2 Copaxone (Glatiramer Acetate, Copolymer 1)
1.2.3 Novantrone (Mitoxantrone)
1.2.4 Gilenya (Fingolimod, Fty720)
1.2.5 Aubagio (Teriflunomide)
1.2.6 Tecfidera (Dimethyl Fumarate)
1.2.7 Firategrast (Sb683699, T-0047)
1.2.8 Siponimod (Baf312)
1.2.9 Others
1.3 Multiple Sclerosis (MS) Drugs Segment by Applications
1.3.1 Global Multiple Sclerosis (MS) Drugs Consumption Comparison by Applications (2014-2025)
1.3.2 RRMS
1.3.3 SPMS
1.3.4 PPMS
1.3.5 PRMS
1.4 Global Multiple Sclerosis (MS) Drugs Overall Market
1.4.1 Global Multiple Sclerosis (MS) Drugs Revenue (2014-2025)
1.4.2 Global Multiple Sclerosis (MS) Drugs Production (2014-2025)
1.4.3 North America Multiple Sclerosis (MS) Drugs Status and Prospect (2014-2025)
1.4.4 Europe Multiple Sclerosis (MS) Drugs Status and Prospect (2014-2025)
1.4.5 China Multiple Sclerosis (MS) Drugs Status and Prospect (2014-2025)
1.4.6 Japan Multiple Sclerosis (MS) Drugs Status and Prospect (2014-2025)
1.4.7 Southeast Asia Multiple Sclerosis (MS) Drugs Status and Prospect (2014-2025)
1.4.8 India Multiple Sclerosis (MS) Drugs Status and Prospect (2014-2025)
2 Manufacturing Cost Structure Analysis
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Multiple Sclerosis (MS) Drugs
2.3 Manufacturing Process Analysis of Multiple Sclerosis (MS) Drugs
2.4 Industry Chain Structure of Multiple Sclerosis (MS) Drugs
3 Development and Manufacturing Plants Analysis of Multiple Sclerosis (MS) Drugs
3.1 Capacity and Commercial Production Date
3.2 Global Multiple Sclerosis (MS) Drugs Manufacturing Plants Distribution
3.3 Major Manufacturers Technology Source and Market Position of Multiple Sclerosis (MS) Drugs
3.4 Recent Development and Expansion Plans
4 Key Figures of Major Manufacturers
4.1 Multiple Sclerosis (MS) Drugs Production and Capacity Analysis
4.2 Multiple Sclerosis (MS) Drugs Revenue Analysis
4.3 Multiple Sclerosis (MS) Drugs Price Analysis
4.4 Market Concentration Degree
5 Multiple Sclerosis (MS) Drugs Regional Market Analysis
5.1 Multiple Sclerosis (MS) Drugs Production by Regions
5.1.1 Global Multiple Sclerosis (MS) Drugs Production by Regions
5.1.2 Global Multiple Sclerosis (MS) Drugs Revenue by Regions
5.2 Multiple Sclerosis (MS) Drugs Consumption by Regions
5.3 North America Multiple Sclerosis (MS) Drugs Market Analysis
5.3.1 North America Multiple Sclerosis (MS) Drugs Production
5.3.2 North America Multiple Sclerosis (MS) Drugs Revenue
5.3.3 Key Manufacturers in North America
5.3.4 North America Multiple Sclerosis (MS) Drugs Import and Export
5.4 Europe Multiple Sclerosis (MS) Drugs Market Analysis
5.4.1 Europe Multiple Sclerosis (MS) Drugs Production
5.4.2 Europe Multiple Sclerosis (MS) Drugs Revenue
5.4.3 Key Manufacturers in Europe
5.4.4 Europe Multiple Sclerosis (MS) Drugs Import and Export
5.5 China Multiple Sclerosis (MS) Drugs Market Analysis
5.5.1 China Multiple Sclerosis (MS) Drugs Production
5.5.2 China Multiple Sclerosis (MS) Drugs Revenue
5.5.3 Key Manufacturers in China
5.5.4 China Multiple Sclerosis (MS) Drugs Import and Export
5.6 Japan Multiple Sclerosis (MS) Drugs Market Analysis
5.6.1 Japan Multiple Sclerosis (MS) Drugs Production
5.6.2 Japan Multiple Sclerosis (MS) Drugs Revenue
5.6.3 Key Manufacturers in Japan
5.6.4 Japan Multiple Sclerosis (MS) Drugs Import and Export
5.7 Southeast Asia Multiple Sclerosis (MS) Drugs Market Analysis
5.7.1 Southeast Asia Multiple Sclerosis (MS) Drugs Production
5.7.2 Southeast Asia Multiple Sclerosis (MS) Drugs Revenue
5.7.3 Key Manufacturers in Southeast Asia
5.7.4 Southeast Asia Multiple Sclerosis (MS) Drugs Import and Export
5.8 India Multiple Sclerosis (MS) Drugs Market Analysis
5.8.1 India Multiple Sclerosis (MS) Drugs Production
5.8.2 India Multiple Sclerosis (MS) Drugs Revenue
5.8.3 Key Manufacturers in India
5.8.4 India Multiple Sclerosis (MS) Drugs Import and Export
6 Multiple Sclerosis (MS) Drugs Segment Market Analysis (by Type)
6.1 Global Multiple Sclerosis (MS) Drugs Production by Type
6.2 Global Multiple Sclerosis (MS) Drugs Revenue by Type
6.3 Multiple Sclerosis (MS) Drugs Price by Type
7 Multiple Sclerosis (MS) Drugs Segment Market Analysis (by Application)
7.1 Global Multiple Sclerosis (MS) Drugs Consumption by Application
7.2 Global Multiple Sclerosis (MS) Drugs Consumption Market Share by Application (2014-2019)
8 Multiple Sclerosis (MS) Drugs Major Manufacturers Analysis
8.1 Bayer AG
8.1.1 Bayer AG Multiple Sclerosis (MS) Drugs Production Sites and Area Served
8.1.2 Bayer AG Product Introduction, Application and Specification
8.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.1.4 Main Business and Markets Served
8.2 Bayhill Therapeutics
8.2.1 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Production Sites and Area Served
8.2.2 Bayhill Therapeutics Product Introduction, Application and Specification
8.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.2.4 Main Business and Markets Served
8.3 Biogen Idec
8.3.1 Biogen Idec Multiple Sclerosis (MS) Drugs Production Sites and Area Served
8.3.2 Biogen Idec Product Introduction, Application and Specification
8.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.3.4 Main Business and Markets Served
8.4 Cinnagen
8.4.1 Cinnagen Multiple Sclerosis (MS) Drugs Production Sites and Area Served
8.4.2 Cinnagen Product Introduction, Application and Specification
8.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.4.4 Main Business and Markets Served
8.5 Daiichi Sankyo
8.5.1 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Production Sites and Area Served
8.5.2 Daiichi Sankyo Product Introduction, Application and Specification
8.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.5.4 Main Business and Markets Served
8.6 Eli Lilly
8.6.1 Eli Lilly Multiple Sclerosis (MS) Drugs Production Sites and Area Served
8.6.2 Eli Lilly Product Introduction, Application and Specification
8.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.6.4 Main Business and Markets Served
8.7 Fast Forward Llc
8.7.1 Fast Forward Llc Multiple Sclerosis (MS) Drugs Production Sites and Area Served
8.7.2 Fast Forward Llc Product Introduction, Application and Specification
8.7.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.7.4 Main Business and Markets Served
8.8 Antisense Therapeutics
8.8.1 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Production Sites and Area Served
8.8.2 Antisense Therapeutics Product Introduction, Application and Specification
8.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.8.4 Main Business and Markets Served
8.9 Apitope
8.9.1 Apitope Multiple Sclerosis (MS) Drugs Production Sites and Area Served
8.9.2 Apitope Product Introduction, Application and Specification
8.9.3 Apitope Multiple Sclerosis (MS) Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.9.4 Main Business and Markets Served
8.10 Five Prime Therapeutics
8.10.1 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Production Sites and Area Served
8.10.2 Five Prime Therapeutics Product Introduction, Application and Specification
8.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.10.4 Main Business and Markets Served
8.11 Genmab
8.12 Artielle Immunotherapeutics
8.13 Genzyme
8.14 Glaxosmithkline
8.15 Gw Pharmaceuticals
8.16 Innate Immunotherapeutics
9 Development Trend of Analysis of Multiple Sclerosis (MS) Drugs Market
9.1 Global Multiple Sclerosis (MS) Drugs Market Trend Analysis
9.1.1 Global Multiple Sclerosis (MS) Drugs Market Size (Volume and Value) Forecast 2019-2025
9.2 Multiple Sclerosis (MS) Drugs Regional Market Trend
9.2.1 North America Multiple Sclerosis (MS) Drugs Forecast 2019-2025
9.2.2 Europe Multiple Sclerosis (MS) Drugs Forecast 2019-2025
9.2.3 China Multiple Sclerosis (MS) Drugs Forecast 2019-2025
9.2.4 Japan Multiple Sclerosis (MS) Drugs Forecast 2019-2025
9.2.5 Southeast Asia Multiple Sclerosis (MS) Drugs Forecast 2019-2025
9.2.6 India Multiple Sclerosis (MS) Drugs Forecast 2019-2025
9.3 Multiple Sclerosis (MS) Drugs Market Trend (Product Type)
9.4 Multiple Sclerosis (MS) Drugs Market Trend (Application)
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.3 Multiple Sclerosis (MS) Drugs Customers
11 Market Dynamics
11.1 Market Trends
11.2 Opportunities
11.3 Market Drivers
11.4 Challenges
11.5 Influence Factors
12 Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Author List
13.4 Disclaimer
Figure Picture of Multiple Sclerosis (MS) Drugs
Table Global Multiple Sclerosis (MS) Drugs Production (K Pcs) Growth Rate Comparison by Types (2014-2025)
Figure Global Multiple Sclerosis (MS) Drugs Production Market Share by Types in 2018
Figure Copaxone (Glatiramer Acetate, Copolymer 1) Product Picture
Figure Novantrone (Mitoxantrone) Product Picture
Figure Gilenya (Fingolimod, Fty720) Product Picture
Figure Aubagio (Teriflunomide) Product Picture
Figure Tecfidera (Dimethyl Fumarate) Product Picture
Figure Firategrast (Sb683699, T-0047) Product Picture
Figure Siponimod (Baf312) Product Picture
Figure Others Product Picture
Table Global Multiple Sclerosis (MS) Drugs Consumption (K Pcs) Comparison by Applications (2014-2025)
Figure Global Multiple Sclerosis (MS) Drugs Consumption Market Share by Applications in 2018
Figure RRMS
Figure SPMS
Figure PPMS
Figure PRMS
Figure Global Multiple Sclerosis (MS) Drugs Revenue (Million USD) (2014-2025)
Figure Global Multiple Sclerosis (MS) Drugs Production (K Pcs) (2014-2025)
Figure North America Multiple Sclerosis (MS) Drugs Market Size (Million USD) (2014-2025)
Figure Europe Multiple Sclerosis (MS) Drugs Market Size (Million USD) (2014-2025)
Figure China Multiple Sclerosis (MS) Drugs Market Size (Million USD) (2014-2025)
Figure Japan Multiple Sclerosis (MS) Drugs Market Size (Million USD) (2014-2025)
Figure Southeast Asia Multiple Sclerosis (MS) Drugs Market Size (Million USD) (2014-2025)
Figure India Multiple Sclerosis (MS) Drugs Market Size (Million USD) (2014-2025)
Table Multiple Sclerosis (MS) Drugs Raw Material and Suppliers
Table Manufacturing Cost Structure Analysis of Multiple Sclerosis (MS) Drugs in 2018
Figure Manufacturing Process Analysis of Multiple Sclerosis (MS) Drugs
Figure Industry Chain Structure of Multiple Sclerosis (MS) Drugs
Table Capacity and Commercial Production Date of Key Manufacturers
Table Global Multiple Sclerosis (MS) Drugs Manufacturing Plants Distribution
Table Multiple Sclerosis (MS) Drugs Major Manufacturers Technology Source and Market Position
Table Recent Development and Expansion Plans in Future
Table Multiple Sclerosis (MS) Drugs Capacity (K Pcs) of Major Manufacturers (2014-2019)
Table Multiple Sclerosis (MS) Drugs Production (K Pcs) of Major Manufacturers (2014-2019)
Table Multiple Sclerosis (MS) Drugs Production Market Share of Major Manufacturers (2014-2019)
Figure Multiple Sclerosis (MS) Drugs Production Share by Manufacturers in 2018
Table Multiple Sclerosis (MS) Drugs Revenue (Million US$) of Major Manufacturers (2014-2019)
Table Multiple Sclerosis (MS) Drugs Revenue Market Share of Major Manufacturers (2014-2019)
Figure Multiple Sclerosis (MS) Drugs Revenue Share by Manufacturers in 2018
Table Multiple Sclerosis (MS) Drugs Average Price (USD/Pcs) of Major Manufacturers (2014-2019)
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Global Multiple Sclerosis (MS) Drugs Production by Regions 2014-2019 (K Pcs)
Table Global Multiple Sclerosis (MS) Drugs Production Market Share by Regions 2014-2019
Figure Global Multiple Sclerosis (MS) Drugs Production Market Share by Regions in 2018
Table Global Multiple Sclerosis (MS) Drugs Revenue by Regions 2014-2019 (Million USD)
Table Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Regions 2014-2019
Figure Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Regions in 2018
Table Global Multiple Sclerosis (MS) Drugs Consumption by Regions 2014-2019 (K Pcs)
Table Global Multiple Sclerosis (MS) Drugs Consumption Market Share by Regions 2014-2019
Figure North America Multiple Sclerosis (MS) Drugs Production Growth Rate 2014-2019 (K Pcs)
Figure North America Multiple Sclerosis (MS) Drugs Revenue Growth Rate 2014-2019 (Million USD)
Table North America Multiple Sclerosis (MS) Drugs Production, Consumption Import and Export (K Pcs)
Figure Europe Multiple Sclerosis (MS) Drugs Production Growth Rate 2014-2019 (K Pcs)
Figure Europe Multiple Sclerosis (MS) Drugs Revenue Growth Rate 2014-2019 (Million USD)
Table Europe Multiple Sclerosis (MS) Drugs Production, Consumption Import and Export (K Pcs)
Figure China Multiple Sclerosis (MS) Drugs Production Growth Rate 2014-2019 (K Pcs)
Figure China Multiple Sclerosis (MS) Drugs Revenue Growth Rate 2014-2019 (Million USD)
Table China Multiple Sclerosis (MS) Drugs Production, Consumption Import and Export (K Pcs)
Figure Japan Multiple Sclerosis (MS) Drugs Production Growth Rate 2014-2019 (K Pcs)
Figure Japan Multiple Sclerosis (MS) Drugs Revenue Growth Rate 2014-2019 (Million USD)
Table Japan Multiple Sclerosis (MS) Drugs Production, Consumption Import and Export (K Pcs)
Figure Southeast Asia Multiple Sclerosis (MS) Drugs Production Growth Rate 2014-2019 (K Pcs)
Figure Southeast Asia Multiple Sclerosis (MS) Drugs Revenue Growth Rate 2014-2019 (Million USD)
Table Southeast Asia Multiple Sclerosis (MS) Drugs Production, Consumption Import and Export (K Pcs)
Figure India Multiple Sclerosis (MS) Drugs Production Growth Rate 2014-2019 (K Pcs)
Figure India Multiple Sclerosis (MS) Drugs Revenue Growth Rate 2014-2019 (Million USD)
Table India Multiple Sclerosis (MS) Drugs Production, Consumption Import and Export (K Pcs)
Figure Global Consumption Multiple Sclerosis (MS) Drugs Market Share by Application (2014-2019)
Figure Global Value (Consumption) Multiple Sclerosis (MS) Drugs Market Share by Application (2014-2019)
Table Bayer AG Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Bayer AG Multiple Sclerosis (MS) Drugs Product Introduction, Application and Specification
Table Bayer AG Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Bayer AG Multiple Sclerosis (MS) Drugs Production Growth Rate (2014-2019)
Table Bayer AG Multiple Sclerosis (MS) Drugs Production Market Share (2014-2019)
Figure Bayer AG Multiple Sclerosis (MS) Drugs Revenue Market Share (2014-2019)
Table Bayer AG Multiple Sclerosis (MS) Drugs Main Business and Markets Served
Table Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Introduction, Application and Specification
Table Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Production Growth Rate (2014-2019)
Table Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Production Market Share (2014-2019)
Figure Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Revenue Market Share (2014-2019)
Table Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Main Business and Markets Served
Table Biogen Idec Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Biogen Idec Multiple Sclerosis (MS) Drugs Product Introduction, Application and Specification
Table Biogen Idec Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Biogen Idec Multiple Sclerosis (MS) Drugs Production Growth Rate (2014-2019)
Table Biogen Idec Multiple Sclerosis (MS) Drugs Production Market Share (2014-2019)
Figure Biogen Idec Multiple Sclerosis (MS) Drugs Revenue Market Share (2014-2019)
Table Biogen Idec Multiple Sclerosis (MS) Drugs Main Business and Markets Served
Table Cinnagen Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Cinnagen Multiple Sclerosis (MS) Drugs Product Introduction, Application and Specification
Table Cinnagen Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Cinnagen Multiple Sclerosis (MS) Drugs Production Growth Rate (2014-2019)
Table Cinnagen Multiple Sclerosis (MS) Drugs Production Market Share (2014-2019)
Figure Cinnagen Multiple Sclerosis (MS) Drugs Revenue Market Share (2014-2019)
Table Cinnagen Multiple Sclerosis (MS) Drugs Main Business and Markets Served
Table Daiichi Sankyo Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Introduction, Application and Specification
Table Daiichi Sankyo Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Daiichi Sankyo Multiple Sclerosis (MS) Drugs Production Growth Rate (2014-2019)
Table Daiichi Sankyo Multiple Sclerosis (MS) Drugs Production Market Share (2014-2019)
Figure Daiichi Sankyo Multiple Sclerosis (MS) Drugs Revenue Market Share (2014-2019)
Table Daiichi Sankyo Multiple Sclerosis (MS) Drugs Main Business and Markets Served
Table Eli Lilly Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Eli Lilly Multiple Sclerosis (MS) Drugs Product Introduction, Application and Specification
Table Eli Lilly Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Eli Lilly Multiple Sclerosis (MS) Drugs Production Growth Rate (2014-2019)
Table Eli Lilly Multiple Sclerosis (MS) Drugs Production Market Share (2014-2019)
Figure Eli Lilly Multiple Sclerosis (MS) Drugs Revenue Market Share (2014-2019)
Table Eli Lilly Multiple Sclerosis (MS) Drugs Main Business and Markets Served
Table Fast Forward Llc Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Introduction, Application and Specification
Table Fast Forward Llc Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Fast Forward Llc Multiple Sclerosis (MS) Drugs Production Growth Rate (2014-2019)
Table Fast Forward Llc Multiple Sclerosis (MS) Drugs Production Market Share (2014-2019)
Figure Fast Forward Llc Multiple Sclerosis (MS) Drugs Revenue Market Share (2014-2019)
Table Fast Forward Llc Multiple Sclerosis (MS) Drugs Main Business and Markets Served
Table Antisense Therapeutics Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Introduction, Application and Specification
Table Antisense Therapeutics Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Antisense Therapeutics Multiple Sclerosis (MS) Drugs Production Growth Rate (2014-2019)
Table Antisense Therapeutics Multiple Sclerosis (MS) Drugs Production Market Share (2014-2019)
Figure Antisense Therapeutics Multiple Sclerosis (MS) Drugs Revenue Market Share (2014-2019)
Table Antisense Therapeutics Multiple Sclerosis (MS) Drugs Main Business and Markets Served
Table Apitope Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Apitope Multiple Sclerosis (MS) Drugs Product Introduction, Application and Specification
Table Apitope Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Apitope Multiple Sclerosis (MS) Drugs Production Growth Rate (2014-2019)
Table Apitope Multiple Sclerosis (MS) Drugs Production Market Share (2014-2019)
Figure Apitope Multiple Sclerosis (MS) Drugs Revenue Market Share (2014-2019)
Table Apitope Multiple Sclerosis (MS) Drugs Main Business and Markets Served
Table Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Introduction, Application and Specification
Table Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Production Growth Rate (2014-2019)
Table Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Production Market Share (2014-2019)
Figure Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Revenue Market Share (2014-2019)
Table Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Main Business and Markets Served
Table Genmab Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Genzyme Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Glaxosmithkline Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Table Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Production Sites and Area Served
Figure Global Multiple Sclerosis (MS) Drugs Production (K Pcs) Growth Rate Forecast 2019-2025
Figure Global Multiple Sclerosis (MS) Drugs Revenue (Million USD) Growth Rate Forecast 2019-2025
Figure Global Multiple Sclerosis (MS) Drugs Sales Price (USD/Pcs) Forecast 2019-2025
Figure North America Multiple Sclerosis (MS) Drugs Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure North America Multiple Sclerosis (MS) Drugs Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Europe Multiple Sclerosis (MS) Drugs Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Europe Multiple Sclerosis (MS) Drugs Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure China Multiple Sclerosis (MS) Drugs Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure China Multiple Sclerosis (MS) Drugs Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Japan Multiple Sclerosis (MS) Drugs Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Japan Multiple Sclerosis (MS) Drugs Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Southeast Asia Multiple Sclerosis (MS) Drugs Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Southeast Asia Multiple Sclerosis (MS) Drugs Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure India Multiple Sclerosis (MS) Drugs Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure India Multiple Sclerosis (MS) Drugs Revenue Growth Rate Forecast 2019-2025 (Million USD)
Table Global Production (K Pcs) of Multiple Sclerosis (MS) Drugs by Type (2019-2025)
Table Global Consumption (K Pcs) of Multiple Sclerosis (MS) Drugs by Application (2019-2025)
Table Multiple Sclerosis (MS) Drugs Distributors List
Table Multiple Sclerosis (MS) Drugs Customers List
Table Market Key Trends
Table Key Opportunities
Table Market Key Drivers
Table Key Challenges
Table Key Influence Factors
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
多発性硬化症の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Multiple sclerosis is a chronic, inflammatory medical condition, which results in demyelination, axonal transection, and neurodegeneration of the nerve cells of the brain and spinal cord. The immune system of the body targets the neurons within the CNS and damages the myelin sheath. It is a potentia…- 二次性進行性多発性硬化症薬のグローバル市場調査 2019年 The global Secondary Progressive Multiple Sclerosis Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Secondary Progressive Multiple Sclerosis Drug volume and value at global level, regional leve…
- 二次性進行性多発性硬化症薬のグローバル市場調査 2019年 The global Secondary Progressive Multiple Sclerosis Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Secondary Progressive Multiple Sclerosis Drug volume and value at global level, regional leve…
- 血液脳関門輸送薬のグローバル市場調査 2019年 The global Blood-Brain Barrier Transport Drugs market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Blood-Brain Barrier Transport Drugs volume and value at global level, regional level and company level.…
- 多回使用バイオリアクターのグローバル市場調査 2019年 The global Multiple-use Bioreactors market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Multiple-use Bioreactors volume and value at global level, regional level and company level. From a global perspec…